Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference41 articles.
1. US Food and Drug Administration. Guidance for industry: expedited programs for serious conditions—drugs and biologics [Internet]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products. Accessed June 2023 [cited 1 Feb 2023].
2. Ballreich J, Socal M, Bennett CL, Schoen MW, Trujillo A, Xuan A, et al. Medicare spending on drugs with accelerated approval. Ann Intern Med. 2022;175:938–44.
3. Johnson JR, Ning Y-M, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103:636–44.
4. Sachs RE, Gavulic KA, Donohue JM, Dusetzina SB. Recent trends in Medicaid spending and use of drugs with US Food and Drug Administration accelerated approval. JAMA Health Forum Am Med Assoc. 2021;2: e213177.
5. Ribeiro TB, Buss L, Wayant C, Nobre MRC. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018. PLoS One. 2020;15: e0236345.